Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Estrogen response in luminal breast cancer.

Rangel LB, Huang TH.

Oncotarget. 2013 Oct;4(10):1548-9. No abstract available.

PMID:
24077736
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.

PMID:
23950888
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.

Groenendijk FH, Zwart W, Floore A, Akbari S, Bernards R.

Breast Cancer Res Treat. 2013 Aug;140(3):475-84. doi: 10.1007/s10549-013-2648-1. Epub 2013 Aug 4.

PMID:
23912957
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA.

Breast Cancer Res. 2011 Jan 28;13(1):R11. doi: 10.1186/bcr2819.

PMID:
21276249
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.

Gorski JJ, Kennedy RD, Hosey AM, Harkin DP.

Clin Cancer Res. 2009 Mar 1;15(5):1514-8. doi: 10.1158/1078-0432.CCR-08-0640. Epub 2009 Feb 17. Review.

PMID:
19223511
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer.

Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, Sisci D.

Curr Cancer Drug Targets. 2008 Nov;8(7):597-610. Review.

PMID:
18991569
[PubMed - indexed for MEDLINE]
7.

miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.

Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.

Endocr Relat Cancer. 2013 Feb 18;20(1):91-102. doi: 10.1530/ERC-12-0207. Print 2013 Feb.

PMID:
23183268
[PubMed - indexed for MEDLINE]
Free Article
8.

Expression of estrogen receptors alpha and beta in early steps of human breast carcinogenesis.

Roger P, Esslimani-Sahla M, Delfour C, Lazennec G, Rochefort H, Maudelonde T.

Adv Exp Med Biol. 2008;617:139-48. doi: 10.1007/978-0-387-69080-3_13. Review. No abstract available.

PMID:
18497038
[PubMed - indexed for MEDLINE]
9.

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?

Lakhani SR, Khanna KK, Chenevix-Trench G.

Breast Cancer Res. 2010;12(2):104. doi: 10.1186/bcr2483. Epub 2010 Mar 19.

PMID:
20346095
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Mechanisms of estrogen receptor-α upregulation in breast cancers.

Miyoshi Y, Murase K, Saito M, Imamura M, Oh K.

Med Mol Morphol. 2010 Dec;43(4):193-6. doi: 10.1007/s00795-010-0514-3. Epub 2011 Jan 26. Review.

PMID:
21267694
[PubMed - indexed for MEDLINE]
11.

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.

Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.

PMID:
20730598
[PubMed - indexed for MEDLINE]
12.

The origin of estrogen receptor alpha-positive and alpha-negative breast cancer.

Clarke RB, Sims AH, Howell A.

Adv Exp Med Biol. 2008;617:79-86. doi: 10.1007/978-0-387-69080-3_7. Review. No abstract available.

PMID:
18497032
[PubMed - indexed for MEDLINE]
13.

Analysis of the ERalpha germline PvuII marker in breast cancer risk.

González-Mancha R, Galán JJ, Crespo C, Iglesias Pérez L, González-Perez A, Morón FJ, Moreno Nogueira JA, Real LM, Pascual MH, Ruiz A, Royo JL.

Med Sci Monit. 2008 Mar;14(3):CR136-43.

PMID:
18301357
[PubMed - indexed for MEDLINE]
14.

Re: KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer (Int J Cancer 123: 2239-2246, 2008).

Geradts J.

Int J Cancer. 2009 May 1;124(9):2243-4; author reply 2245. doi: 10.1002/ijc.24156. No abstract available.

PMID:
19115215
[PubMed - indexed for MEDLINE]
15.

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M.

Breast Cancer Res Treat. 2011 Jan;125(1):35-42. doi: 10.1007/s10549-010-0819-x. Epub 2010 Mar 11.

PMID:
20221692
[PubMed - indexed for MEDLINE]
16.

The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo.

Murphy LC, Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M, Watson PH.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):90-5. doi: 10.1016/j.jsbmb.2009.01.017. Epub 2009 Feb 6. Review.

PMID:
19429437
[PubMed - indexed for MEDLINE]
17.

"Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen.

Fowler AM, Santen RJ, Allred DC.

J Clin Oncol. 2009 Jul 20;27(21):3413-5. doi: 10.1200/JCO.2009.21.8776. Epub 2009 Jun 1. No abstract available.

PMID:
19487375
[PubMed - indexed for MEDLINE]
Free Article
18.

Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer.

Li Y, Li Y, Wedrén S, Li G, Charn TH, Desai KV, Bonnard C, Czene K, Humphreys K, Darabi H, Einarsdóttir K, Heikkinen T, Aittomäki K, Blomqvist C, Chia KS, Nevanlinna H, Hall P, Liu ET, Liu J.

Breast Cancer Res. 2011 Jan 26;13(1):R10. doi: 10.1186/bcr2817.

PMID:
21269472
[PubMed - indexed for MEDLINE]
Free PMC Article
19.
20.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk